| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9463161 | ASTRAZENECA AB | Compositions for pulmonary delivery of long-acting muscarinic antagonists and associated methods and systems |
May, 2030
(6 years from now) | |
| US8703806 | ASTRAZENECA AB | Compositions, methods and propellant-based systems for respiratory delivery of glycopyrrolate and one or more active agents |
May, 2030
(6 years from now) | |
| US8808713 | ASTRAZENECA AB | Compositions for pulmonary delivery of long-acting β2 adrenergic receptor agonists and associated methods and systems |
May, 2030
(6 years from now) | |
| US8324266 | ASTRAZENECA AB | Compositions, methods and systems for respiratory delivery of two or more active agents |
May, 2030
(6 years from now) | |
| US9415009 | ASTRAZENECA AB | Compositions, methods and systems for respiratory delivery of two or more active agents |
May, 2030
(6 years from now) | |
| US10716753 | ASTRAZENECA AB | Compositions for pulmonary delivery of long-acting muscarinic antagonists or long-acting B2 adrenergic receptor agonists and associated methods and systems |
May, 2030
(6 years from now) | |
| US8815258 | ASTRAZENECA AB | Compositions, methods and systems for respiratory delivery of two or more active agents |
Mar, 2031
(7 years from now) | |
| US11331442 | ASTRAZENECA AB | Drug delivery systems and related methods |
Oct, 2038
(15 years from now) | |
Breztri Aerosphere is owned by Astrazeneca Ab.
Breztri Aerosphere contains Budesonide; Formoterol Fumarate; Glycopyrrolate.
Breztri Aerosphere has a total of 8 drug patents out of which 0 drug patents have expired.
Breztri Aerosphere was authorised for market use on 23 July, 2020.
Breztri Aerosphere is available in aerosol, metered;inhalation dosage forms.
Breztri Aerosphere can be used as use for the maintenance treatment of patients with chronic obstructive pulmonary disease (copd).
The generics of Breztri Aerosphere are possible to be released after 05 October, 2038.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination (NC) | Jul 23, 2023 |
Drugs and Companies using BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE ingredient
Market Authorisation Date: 23 July, 2020
Treatment: Use for the maintenance treatment of patients with chronic obstructive pulmonary disease (copd)
Dosage: AEROSOL, METERED;INHALATION
BREZTRI AEROSPHERE family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic